

# REFERENCES

- Acsadi G, Lochmuller H, Jani A, Huard J, Massie B, Prescott S, et al. (1996). Dystrophin expression in muscles of *mdx* mice after adenovirus-mediated *in vivo* gene transfer. *Human Gene Therapy*. **7(2)**: 129-40.
- Addison CL, Braciak T, Ralston R, Muller WJ, Gaudie J, and Graham FL (1995). Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. *Proceedings of the National Academy of Sciences of the United States of America*. **92(18)**:8522-6.
- American Cancer Society. (2003). Retrieved January 10, 2003, from <http://www.cancer.org>
- Anvari, M (2002). *Transcript of Interview with Dr. Mehran Anvari*. Recorded by Tang, Jennifer Clara.
- Anvari, M. Proposal for Telerobotic Endoscopy. *Centre for Minimal Access Press Package*.
- Beauchamp TL, Cook RR, Fayerweather WE, Raabe GK, Thar WE, Cowles SR, et al. (1991). Ethical guidelines for epidemiologists. *Journal of Clinical Epidemiology*. **44(Suppl. 1)**: 151S-69S.
- Beauchamp, T.L. and Childress, J.F. (1994). *Principles of Biomedical Ethics* (4<sup>th</sup> ed.). New York: Oxford University Press.
- Beauchamp, T.L. and Walters L. (1999). *Contemporary Issues in Bioethics* (5<sup>th</sup> ed.). Belmont, CA: Wadsworth Publishing Company.
- Bett AJ, Haddara W, Prevec L, and Graham FL (1994). An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. *Proceedings of the National Academy of Sciences of the United States of America*. **91(19)**: 8802-6.
- Bilbao G, Feng M, Rancourt C, Jackson WH Jr., and Curiel DT (1997). Adenoviral/retroviral vector chimeras: A novel strategy to achieve high-efficiency stable transduction *in vivo*. *FASEB Journal*. **11(8)**: 624-34.
- Black, D. (1994). Absolute confidentiality?. *Principles of Health Care Ethics*. Ed. Raanan Gillon. John Wiley & Sons Ltd.
- Bonsor, K. (n.d.). *How Robotic Surgery Will Work*. From <http://www.howstuffworks.com/robotic-surgery1.htm>
- Bradley KA, Mogridge J, Mourez M, Collier RJ, and Young JA (2001). Identification of the Cellular Receptor for Anthrax Toxin. *Nature*. **414(6860)**: 225-9.
- Brehl, R. (2002). The Cutting Edge. *Time Magazine*. September 23, 2002
- Campbell, N.A., Reece, J., and Mitchell, L. (1999). *Biology* (5<sup>th</sup> ed.). California: Addison Wesley Longman, Inc. 320-325.
- CANVAC (2002). *Press release: Important Canadian breakthrough in HIV vaccine research*. Retrieved January 11, 2003, from [http://www.canvacc.org/publik/wnews/PRESS\\_RELEASE.pdf](http://www.canvacc.org/publik/wnews/PRESS_RELEASE.pdf)
- CDC (1987a). *Morbidity and Mortality Weekly Report: Revision of the surveillance case definition of acquired immunodeficiency syndrome*. **36**: 3S-15S.
- CDC (1987b). *Morbidity and Mortality Weekly Report: Classification for human immunodeficiency virus (HIV) infection in children under 13 years of age*. **35**: 224-35.
- CDC (1992). *Morbidity and Mortality Weekly Report: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults*. **41**: 1-19.
- Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, et al. (1991). High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. *N Engl J Med*. **324(14)**: 954-60.
- Clark, T. (2002). Third anthrax toxin revealed. Accessed, August 09, 2002 at
- Connor RI and Ho DD (1994). Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. *J Virol*. **68(7)**: 4400-8.
- Cooper DA, Gold J, Maclean P, Donovan B, Finlayson R, Barnes TG, et al. (1985). Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. *Lancet*. **1(8428)**: 537-40.
- Daar ES, Moudgil T, Meyer RD, and Ho DD (1991). Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. *N Engl J Med*. **324(14)**: 961-4.
- Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, and Weiss RA (1984). The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. *Nature*. **312(5996)**: 763-7.
- Depression (n.d.). Retrieved January 5, 2003, from <http://www.mayoclinic.com/>
- Depression (n.d.). Retrieved January 5, 2003, from National Institute of Mental Health Web. Site: <http://www.nimh.nih.gov/publicat/depression.cfm#ptdep2>
- Depression and Antidepressants: A Guide. Madison Institute of Medicine. Retrieved January 5, 2003, from Madison Institute of Medicine Website Site: [http://www.miminc.org/sample\\_depress01.html](http://www.miminc.org/sample_depress01.html)
- Dodek DY and Dodek A (1997). From Hippocrates to facsimile: protecting patient confidentiality is more difficult and more important than ever before. *Canadian Medical Association Journal*. **156(6)**: 847-52.
- Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, et al. (1998). Proteolytic Inactivation of MAP-Kinase-Kinase by Anthrax Lethal Factor. *Science*. **280(5364)**: 734-7.
- Dumais N, Patrick A, Moss RB, Davis HL, and Rosenthal KL (2002). Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. *J Infect Dis*. **186**: 1098-105.
- ECure Me. (2002). Retrieved January 12, 2003, from <http://www.ecureme.com>
- English, D.C. (1994). *Bioethics: a clinical guide for medical students* (1<sup>st</sup> ed.). New York: W.W. Norton & Company.
- Evans D and Lahoti S (2000). Adenovirus in cancer therapy: a gastrointestinal case study. *Gastroenterology Nursing*. **23(1)**: 16-8.
- Fisher KJ, Kelley WM, Burda JF and Wilson JM (1996). A novel adenovirus-Adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. *Human Gene Therapy*. **7(17)**: 2079-87.
- Friedlander AM (2001). Tackling Anthrax. *Nature*. **414(6850)**: 160-1.
- Gettman MT, Blute ML, Peschel R and Bartsch G (2002). Current Status of Robotics in Urologic Laparoscopy. *European Urology*. **42(2)**: 106-12.
- Gold PW and Charney DS (2002). Depression: A Disease of the Mind, Brain, and Body. *American Journal of Psychiatry*. **159(11)**: 1826.
- Goldman MJ, Yang Y, and Wilson JM (1995). Gene therapy in a xenograft model of cystic fibrosis lung corrects chloride transport more effectively than the sodium defect. *Nature Genetics*. **9(2)**: 126-31.

- Gostin LO (1995). Genetic privacy. *Journal of Law, Medicine and Ethics*. **23(4)**: 320-30.
- Graham FL (2000). Adenovirus vectors for high-efficiency gene transfer into mammalian cells. *Immunology Today*. **21(9)**: 426-8.
- Graham FL, Smiley J, Russell WC, and Nairn R (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *Journal of General Virology*. **36(1)**: 59-74.
- Halstead, L. (1998). *Managing Post-Polio*. Washington, D.C: NRH Press.
- Halstead, L. and Grimby, G. (1995). *Post-Polio Syndrome*. Philadelphia: Hanley and Belfus Inc.
- Harkness KL, Bagby RM, Joffe RT, and Levitt A (2002). Major Depression, Chronic Minor Depression, and the Five-Factor Model of Personality. *European Journal of Personality*. **16**: 271-81.
- Harrington KJ, Bateman AR, Melcher AA, Ahmed A and Vile RG (2002). Cancer Gene Therapy: Part I. Vector development and regulation of gene expression. *Clinical Oncology*. **14(1)**: 3-16.
- Hippocrates (1994). *Translated Works*. Vol. 1. Ed, Trans. Francis Adams. New York, N.Y.: Loeb Publishing.
- Hitt MM and Graham FL (2000). Adenovirus vectors for human gene therapy. *Advances in Virus Research*. **55**: 479-505.
- Hitt, M., Bett, A.J., Prevec, L., and Graham, F.L. (1994). Construction and propagation of human adenovirus vectors. *Cell Biology: A Laboratory Handbook*. Academic Press, Inc. 479-90. <http://www.nature.com/nsu/020121/020121-6.html>
- Hunt KK and Vorburger SA (2002). Tech.Sight. Gene therapy. Hurdles and hopes for cancer treatment. *Science*. **297(5580)**: 415-6.
- Imler LL (1995). Adenovirus vectors as recombinant viral vaccines. *Vaccine*. **13(13)**: 1143-51.
- Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM et al. (1999). Anthrax as a Biological Weapon: Medical and Public Health Management. *Journal of the American Medical Association*. **281(18)**: 1735-45.
- Janeway, C.A., Travers, P., Walport, M., and Shlomchik, M. (2001). *Immunobiology* (5<sup>th</sup> ed.). New York: Garland Publishing.
- Kafri T, Morgan D, Krahl T, Sarvetnick N, Sherman L, and Verma I (1998). Cellular immune response to adenoviral vector injected cells does not require *de novo* viral gene expression: Implications for gene therapy. *Proceedings of the National Academy of Sciences of the United States of America*. **95(19)**: 11377-82.
- Kaufman, M. (2001). *Overcoming Teen Depression: A Guide for Parents*. New York: Firefly books Inc.
- Kay MA, Landen CN, Rothenberg SR, Taylor LA, Leland F, Wiehle S., et al. (1994). *In vivo* hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs. *Proceedings of the National Academy of Sciences of the United States of America*. **91(6)**: 22353-7.
- Keeton W.T. and Gould J.L. (1986). *Biological Sciences* (4<sup>th</sup> ed.). New York: W.W. Norton & Company.
- Kimball, J.W. (2000). *Kimball's Biology Pages: AIDS*. Retrieved January 9, 2003, from <http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/A/AIDS.html#Infection>
- Kimball, J.W. (2002). *Kimball's Biology Pages: B cells and T cells*. Retrieved January 5, 2003, from [http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/B/B\\_and\\_Tcells.html#cd4](http://users.rcn.com/jkimball.ma.ultranet/BiologyPages/B/B_and_Tcells.html#cd4)
- Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Hercend T, et al. (1984). T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. *Nature*. **312(5996)**: 767-8.
- Knox EG (1992). Confidential medical records and epidemiological research. *BMJ*. **304(6829)**: 727-8.
- Levine, R.J. (1986). *Ethics and regulation of clinical research* (2<sup>nd</sup> ed.). Baltimore, MA: Urban and Schwarzenberg.
- Licinion A and Pappaspyropoulos V (2000). Telesurgery. *Ultrasound in Med. & Biol.* **26(Suppl. 1)**: 45S-7S.
- Liddington RC (2002). A molecular full nelson. *Nature*. **415(6870)**: 373-374.
- Lo, B. (2000). *Resolving ethical dilemmas: a guide for clinicians* (2<sup>nd</sup> ed). Philadelphia, PA: Lippincott Williams & Wilkins.
- Lohr, J.T. (1999). Myxoma. *The Gale Encyclopedia of Medicine - 5 volumes*. Farmington Hills, Mich.: Gale Research.
- Maione D, Della Rocca C, Giannetti P, D'Arrigo R, Liberatoscioli L, Franlin LL, et al. (2001). An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. *Proceedings of the National Academy of Sciences of the United States of America*. **98(11)**: 5986-91.
- Manji H (2003). Depression, III: Treatments. *Am J Psychiatry*. **160(1)**: 24.
- McDougal JS, Kennedy MS, Sligh JM, Cort SP, Mawle A, and Nicholson JK (1986). Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. *Science*. **231(4736)**: 382-5.
- McDougal JS, Mawle A, Cort SP, Nicholson JK, Cross GD, Scheppler-Campbell JA, et al. (1985). Cellular tropism of the human retrovirus HTLV-III/LAV. Role of T cell activation and expression of the T4 antigen. *J Immunol*. **135(5)**: 3151-62.
- Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA (2002). Clinical depression and inflammatory risk markers for coronary disease. *The American Journal of Cardiology*. **90(12)**: 1279-83.
- Morral, N., O'Neal, W., Rice, K., Leland, M., Kaplan, J., Piedra, P. A., Zhou, H., Parks, R. J., Velji, R., Aguilar-Cordova, E., Wadsworth, S., Graham, F. L., Kochanek, S., Carey, K. D. and Beaudet, A. L. "Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons." *Proceedings of the National Academy of Sciences of the United States of America*, October 1999, Vol. **96(22)**:12816-12821.
- Morsy, M.A., Gu, M., Motzel, S., Zhao, J., Lin, J., Su, Q., Allen, H., Franlin, L., Parks, R.J., Graham, F.L., Kochanek, S., Bett, A.J. and Caskey, C.T. "An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene." *Proceedings of the National Academy of Sciences of the United States of America*, July 1998, Vol. **95(14)**:7866-7871.
- Mourez M, Kane RS, Mogridge J, Metallo S, Deschatelets P, Sellman BR, et al. (2001). Designing a Polyvalent Inhibitor of Anthrax Toxin. *Nature Biotechnology*. **19(10)**: 958-961.
- NIAID (1998). *Understanding Vaccines*. Retrieved January 12, 2003, from <http://www.niaid.nih.gov/publications/vaccine/undvacc.htm>
- NIAID (2001). *How HIV causes AIDS: NIAID Fact Sheet*. Retrieved January 9, 2003, from <http://www.niaid.nih.gov/factsheets/howhiv.htm>
- Olsnes S and Wesche J (2001). Fighting Anthrax with a Mutant Toxin. *Science*. **292(5517)**: 647-8.
- Operation Lindbergh*. (n.d.). Retrieved February, 2002 from <http://www.websurg.com/lindbergh/index.cfm>
- Pantaleo G, Graziosi C, and Fauci AS (1993). New concepts in the immunopathogenesis of human immunodeficiency virus infection. *N Engl J Med*. **328(5)**: 327-35.

- Parks, R.J., Chen, L., Martina, A., Uma, S., Michael, A.R. and Graham, F.L. "A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal." *Proceedings of the National Academy of Sciences of the United States of America*, November 1996, Vol. **93**:13565-13570.
- Posener JA, Wang L, Price JL, Gado MH, Province MA, Miller MI, et al. (2003). High-Dimensional Mapping of the Hippocampus in Depression. *Am. J. Psychiatry*. **160(1)**: 83-9.
- Rapaport MH, Judd LL, Schettler PJ, Yonkers KA, Thase ME, Kupfer DJ, et al. (2002). A Descriptive Analysis of Minor Depression. *American Journal of Psychiatry*. **159(4)**: 637-43.
- Reynen K (1995). Cardiac Myxomas. *The New England Journal of Medicine*. **333(24)**: 1610-7.
- Reynolds, P.N. and Curiel, D.T. (1999) Strategies to adapt adenoviral vectors for gene therapy applications: Targeting and integration. T. Friedmann (Ed.), *In The Development of Human Gene Therapy*. (p. 111-130). New York: Cold Spring Harbor Laboratory Press.
- Richman DD and Bozzette SA (1994). The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. *J Infect Dis*. **169(5)**: 968-74.
- Ries, S. and Korn, W.M. (2002) ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. *British Journal of Cancer*, Vol. **86(1)**:5-11.
- Robot2.jpg (n.d.). Retrieved January 5, 2003, from Ohio State University website: <http://www.ohioheartsurgery.com/robot2.jpg>
- Rocque CL (2001). The anti-bioterrorist handbook.. *The Medical Post*. 37(27).
- Ryan, K.J. (1994) *Sherris medical microbiology: an introduction to infectious diseases*. (451-463). Connecticut: Appleton & Lange Press.
- Satava RM (1992). Robotics, telepresence and virtual reality: a critical analysis of the future of surgery. *Min Invas Ther*. **1**: 357-63.
- Sellman BR, Mourez M and Collier RJ (2001). Dominant-Negative Mutants of a Toxin Subunit: An Approach to Therapy of Anthrax.. *Science*. **292(5517)**: 695-697.
- Siegler M (1982). Confidentiality in medicine: a decrepit concept. *New England Journal of Medicine*. **307(24)**: 1518-21.
- St John R and Giroux C (2002). Terrorism and Public Health: The Little Known Equation. *Canadian Journal of Public Health*. **93(3)**: 165-6.
- Statistics Canada. (n.d.). Retrieved January 5, 2003, from <http://www.statecan.ca/Daily/English/020919/d020919a.htm>
- Stewart. A. K., Lassam, N., Quirt, I. C., Bailey, D. J., Rotstein, L. E., Krajden, M., Dessureault, S., Gallenger, S., Cappe, D., Wan, Y. H., Addison, C. A., Moen, R., Gauldie, J. and Graham, F. L. (1999) Adenovector-mediated gene delivery of interleukin 2 in metastatic breast cancer and melanoma: results of a phase I clinical trial. *Gene Therapy*, Vol. **6**:350-363.
- Stone, B.J. (n.d.). *Degrees of Freedom*. Retrieved January 5, 2003, from University of Western Australia website: <http://www.mech.uwa.edu.au/bjs/Vibration/OneDOF/DOF.html>
- Strauss E (1998). New Clue to How Anthrax Kills. *Science*. **280(5364)**: 676.
- Tindall B and Cooper DA (1991). Primary HIV infection: host responses and intervention strategies. *AIDS*. **5(1)**: 1-14. UNAIDS (2002). *AIDS Epidemic Update: December 2002*. Retrieved January 11, 2003, from <http://www.unaids.org/worldaidsday/2002/press/Epiupdate.html>
- Tollefson, A.E., Stewart, A.R., Yei, S., Saha, S.K. and Wold, W.S.M. (1991) The 10,400- and 14,500-Dalton proteins encoded by region E3 of adenovirus form a complex and function together to don-regulate the epidermal growth factor receptor." *Journal of Virology*, Vol. **65(6)**:3095-3105.
- UK Childhood Cancer Study Investigators (1999). Exposure to power frequency magnetic fields and the risk of childhood cancer. *The Lancet*. **354(9194)**: 1925-31.
- Vorburger, S.A. and Hunt, K.K. (2002) Adenoviral Gene Therapy. *The Oncologist*, Vol. **7(1)**:46-59.
- Webster's Dictionary. (2003). Retrieved January 10, 2003, from <http://www.dictionary.com>
- Wold, W.S.M. and Gooding, L.R. (1991) Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. *Virology*, Vol. **184**:1-8.
- World Health Organization. (2001). Mental Health: New Understanding, New Hope. *The World Health Report 2001*. Geneva: World Health Organization.
- Young, J.A. and Collier, R.J. (2002). Attacking Anthrax. *Scientific American*. March 2002: 50-9.
- Zeus™ Robot Surgical System. (2003). Retrieved January 5, 2003, from <http://www.computermotion.com/>